N-[(2Z)-5-tert-butyl-3-isobutyl-1,3-thiazol-2(3H)-ylidene]-2-(2-pyrrolidin-1-ylethoxy)-5-(trifluoromethyl)benzamide | 1231954-97-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(2Z)-5-tert-butyl-3-isobutyl-1,3-thiazol-2(3H)-ylidene]-2-(2-pyrrolidin-1-ylethoxy)-5-(trifluoromethyl)benzamide
• CAS: 1231954-97-4
• 化学式: C₂₅H₃₄F₃N₃O₂S
• 分子量: 497.625
• InChiKey: DYKNIKNRZUKUIO-FAJYDZGRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.74
• 重原子数：
  34.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  46.83
• 氢给体数：
  0.0
• 氢受体数：
  5.0

文献信息

• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Frost Jennifer M.

  公开号：US20100216760A1

  公开（公告）日：2010-08-26

  Disclosed herein are cannabinoid receptor ligands of formula (I) wherein L 1 , A 1 , R 1g , z, R 2 , R 3 , and R 4 are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

  本文公开了式(I)的大麻素受体配体，其中L1、A1、R1g、z、R2、R3和R4如规范中所定义。还提出了包含这些化合物的组合物以及使用这些化合物和组合物治疗疾病和疾病的方法。
• THIAZOLES AS CANNABINOID RECEPTOR LIGANDS
  申请人：AbbVie Inc.

  公开号：EP3026046A1

  公开（公告）日：2016-06-01

  Disclosed herein are cannabinoid receptor ligands of formula (I) wherein L1, A1, R1g, z, R2, R3, and R4 are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented. (I)

  本文公开了式 (I) 的大麻素受体配体，其中 L1、A1、R1g、z、R2、R3 和 R4 如说明书中所定义。还介绍了包含此类化合物的组合物以及使用此类化合物和组合物治疗疾病的方法。 (I)
• Thiazoles as cannabinoid receptor ligands
  申请人：Abbott Laboratories

  公开号：EP2376462A1

  公开（公告）日：2011-10-19
• US8895592B2
  申请人：——

  公开号：US8895592B2

  公开（公告）日：2014-11-25
• [EN] THIAZOLES AS CANNABINOID RECEPTOR LIGANDS<br/>[FR] THIAZOLES EN TANT QUE LIGANDS DES RÉCEPTEURS DES CANNABINOÏDES
  申请人：ABBOTT LAB

  公开号：WO2010071783A1

  公开（公告）日：2010-06-24

  Disclosed herein are cannabinoid receptor ligands of formula (I) wherein L1, A1, R1g, z, R2, R3, and R4 are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.